Dr. Gieschen on the Side Effects of Radiation Therapy in NSCLC

Video

Holger L. Gieschen, MD, assistant professor, Department of Radiology, the University of Tennessee Health Science Center, radiation oncologist, West Cancer Center, discusses the safety profile of radiation therapy in patients with non–small cell lung cancers (NSCLC).

Holger L. Gieschen, MD, assistant professor, Department of Radiology, the University of Tennessee Health Science Center, radiation oncologist, West Cancer Center, discusses the safety profile of radiation therapy in patients with non—small cell lung cancer (NSCLC).

Side effects of radiation may include skin reactions and some irritation of the lung. Physicians will usually differentiate between acute side effects that may occur when the patient is undergoing treatment and long-term side effects that may manifest months or years after the treatment.

The acute side effects are usually transient and are not cause for concern. Long-term side effects can result in lung fibrosis and diminished lung volume and capacity. As in surgery, the concern is a patient’s insufficient lung capacity after treatment.

One of the most significant side effects that can result from radiation therapy is radiation pneumonitis, which is not due to bacteria or infection, but the radiation itself. Some of these patients require steroid treatments which can be difficult to handle.

Recent Videos
Carol Miao, PhD, a principal investigator at Seattle Children’s Research Institute
Lucas Harrington, PhD, the cofounder and chief scientific officer of Mammoth Biosciences
Miloš Miljković, MD, on mRNA-CAR-T Descartes-08's Potential for Treating Myasthenia Gravis
Manali Kamdar, MD, on Liso-Cel's Ongoing Benefit in the Treatment Lanscape for LBCL
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
David Dimmock, MBBS, on AI-Guided ASO Development for Ultra-Rare Diseases
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg Cells
Luke Roberts, MBBS, PhD, on Challenges in Developing Gene Therapy for Heart Failure
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
© 2024 MJH Life Sciences

All rights reserved.